Intech Investment Management LLC Purchases 22,858 Shares of Biohaven Ltd. (NYSE:BHVN)

Intech Investment Management LLC boosted its holdings in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 202.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,165 shares of the company's stock after purchasing an additional 22,858 shares during the period. Intech Investment Management LLC's holdings in Biohaven were worth $1,276,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in BHVN. Stifel Financial Corp lifted its position in shares of Biohaven by 0.4% during the 3rd quarter. Stifel Financial Corp now owns 6,509,261 shares of the company's stock valued at $325,268,000 after acquiring an additional 28,684 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Biohaven by 5.6% during the third quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company's stock worth $311,142,000 after purchasing an additional 328,099 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Biohaven by 2.6% during the third quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company's stock valued at $85,696,000 after purchasing an additional 44,174 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Biohaven by 745.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock valued at $74,969,000 after purchasing an additional 1,322,922 shares during the period. Finally, ARS Investment Partners LLC increased its stake in Biohaven by 1.0% in the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after purchasing an additional 10,473 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In other news, Director John W. Childs bought 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the purchase, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This represents a 1.43 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 16.00% of the company's stock.

Biohaven Trading Down 4.0 %

Biohaven stock traded down $1.24 during mid-day trading on Tuesday, hitting $29.80. 894,665 shares of the company's stock were exchanged, compared to its average volume of 1,055,183. Biohaven Ltd. has a 1-year low of $26.80 and a 1-year high of $59.53. The stock has a 50 day moving average of $35.65 and a two-hundred day moving average of $41.56. The stock has a market cap of $3.04 billion, a P/E ratio of -3.19 and a beta of 1.27.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). As a group, research analysts predict that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Analyst Ratings Changes

BHVN has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven in a report on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft began coverage on shares of Biohaven in a research report on Tuesday, February 11th. They set a "buy" rating and a $65.00 price objective on the stock. Finally, Morgan Stanley cut their target price on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Biohaven has a consensus rating of "Buy" and an average target price of $63.15.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.